August 22, 2014 5:37 AM ET

Healthcare Equipment and Supplies

Company Overview of Nanomix, Inc.

Company Overview

Nanomix, Inc., a nanoelectronic detection company, develops and manufactures Sensation technology based detection devices for biomolecule and respiratory detection applications. The company offers an ultrasensitive cardiac troponin assay to evaluate heart muscle damage; and an eNO Asthma Management System, a stand-alone breath analysis system for managing asthma that measures exhaled nitric oxide. It also provides environmental monitors to detect low levels of industrial gas for environmental monitoring and demand controlled ventilation; and carbon nanotubes for the detection of various biomolecules and gases a single device with different chemistries. The company’s products are used in the ...

5980 Horton Street

Suite 600

Emeryville, CA 94608

United States

Founded in 2000

Phone:

510-428-5300

Fax:

510-658-0425

Key Executives for Nanomix, Inc.

Chief Executive Officer and President
Age: 63
Executive Chairman
Age: 57
Co-Founder
Co-Founder
Chief Financial Officer and Vice President of Finance
Compensation as of Fiscal Year 2014.

Nanomix, Inc. Key Developments

Nanomix, Inc. Appoints Brian Jung as Vice President of Finance and Chief Financial Officer

Nanomix, Inc. announced the appointment of Brian Jung as Vice President of Finance and Chief Financial Officer. Mr. Jung brings significant financial and executive experience to Nanmix, having served in CFO and executive roles for several healthcare and life science companies.

Nanomix Inc. Closes Private Financing for Approximately $12 Million

Nanomix Inc. announced that is has closed private financing for approximately $12 million. The financing, received from a strategic corporate partner and existing investors, will fund the completion of development, registration clinical trials, and commercial launch of the company's mobile diagnostic platform and initial assays.

Nanomix, Inc. Initiates Clinical Testing of Point of Care IVD Cardiac Panel

Nanomix, Inc. announced that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel. The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and H-FABP, biomarkers often used as an aid in the diagnosis of myocardial infarction (MI). The initial testing will be conducted with approximately 170 normally healthy subjects and will provide baseline performance information that will form the basis of future registration clinical studies. Chest pain is the second leading cause of admittance to Emergency Departments in the US. An early and accurate diagnosis of chest pain complaints is key to achieving improved patient outcomes through earlier treatment intervention. The Omega-3 handheld system is designed for use in the Emergency Department and by pre-hospital First Responders in the field to speed the diagnosis of an MI. The combination of a handheld electronic reader and wholly contained cartridge allow the cardiac test panel to be performed at the point of patient contact, avoiding delays associated with transporting samples to laboratory for traditional testing.

Similar Private Companies By Industry

Company Name Region
Boston Scientific Miami Corporation United States
C&J Wholesale Supply, Inc. United States
Zymo Research Corporation United States
Magellan Diagnostics, Inc. United States
Robert Busse & Co., Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 30, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nanomix, Inc., please visit nano.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.